Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies

Grant Award Details

Grant Type: Clinical Trial Stage Projects
Grant Number: CLIN2-10846
Project Objective: To complete a Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies.

Investigator:
Name: Crystal Mackall
Institution: Stanford University
Type: PI

Disease Focus: B cell cancers, Blood Cancer, Cancer, Leukemia
Human Stem Cell Use: Adult Stem Cell
Cell Line Generation: Adult Stem Cell
Award Value: $11,034,982
Status: Active

Grant Application Details
Application Title: Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies
Public Abstract:

**Therapeutic Candidate or Device**

T cells genetically engineered to express as bispecific Chimeric Antigen Receptor (CAR) targeting CD19 and/or CD22

**Indication**

Patients with relapsed and refractory B cell malignancies

**Therapeutic Mechanism**

T cells expressing the bispecific CAR will recognize cancer cells expressing one of both of the target antigens. Upon recognition, the T cells will become activated, divide, and then kill the cancer cells. Progenitor T cells contained within the larger population will form memory stem cells that will persist and continue to survey the body and kill residual cancer. These cancer killing T cells are designed to persist for years following one treatment with CD19/22-CAR T cells.

**Unmet Medical Need**

50% or less of patients with diffuse large B cell lymphoma and B cell leukemia are cured with standard regimens, that rely on chemotherapy for benefit. CD19/22-CAR T cells effectively kill chemotherapy resistant lymphoma and leukemia and thus could improve cure rates for these aggressive cancers.

**Project Objective**

Phase 1 trial completed

**Major Proposed Activities**

- Demonstrate feasibility of producing CD19/22-CAR T cells
- Assess toxicity of CD19/22-CAR T cells
- Assess clinical activity of CD19/22-CAR T cells in adults with B-ALL and DLBCL.

**Statement of Benefit to California:**

In California, approximately 2000 adults are diagnosed annually with DLBCL and 600 with B-ALL. At least one third will not respond to chemotherapy based treatment and most will die of their disease within one year. The CD19/22-CAR provides a new, potentially effective therapy for these patients. It could demonstrate both a higher response rate and greater long-term effectiveness than the CD19-CAR that has recently received FDA approval for these patients.

Source URL: https://www.cirm.ca.gov/our-progress/awards/phase-1-study-cd19cd22-chimeric-antigen-receptor-car-t-cells-adults-recurrent-or